行情

PHIO

PHIO

Phio Pharmaceuticals Corp
NASDAQ

实时行情|Nasdaq Last Sale

0.8603
-0.0197
-2.24%
盘后: 0.8999 +0.0396 +4.60% 18:10 01/21 EST
开盘
0.8700
昨收
0.8800
最高
0.9112
最低
0.8300
成交量
20.68万
成交额
--
52周最高
4.360
52周最低
0.8130
市值
1,164.39万
市盈率(TTM)
-0.7062
分时
5日
1月
3月
1年
5年
18 Stocks Moving in Friday's Pre-Market Session
Check out these penny stocks insiders are buying
Benzinga · 1天前
28 Stocks Moving In Wednesday's Mid-Day Session
Gainers Immuron Limited (NASDAQ: IMRN) shares jumped 40.2% to $3.5887. Immuron received funding of A$6.2 ($4.45) million from the U.S Department of Defense to examine a dosing regimen for Travelan more suited for use by the military.
Benzinga · 01/12 17:00
Immuron、Immix 领跑医疗保健股;飞利浦、Prothena 成为失败者
Gainers: Immuron (NASDAQ:IMRN) +43%. Immix Biopharma (NASDAQ:IMMX) +28%. Sonendo (NYSE:SONX) +16%. IRIDEX (NASDAQ:IRIX) +13%. NEXGEL (NXGL) +10%. Losers: Koninklijke Philips (NYSE:PHG) -15%. Prothena (NASDAQ:PRTA) -13%. Biogen (NASDAQ:BIIB) -10%. Phio Phar...
Seekingalpha · 01/12 15:02
周三盘前交易中的 15 只股票
Gainers Kidpik Corp. (NASDAQ: PIK) rose 34.4% to $8.13 in pre-market trading after jumping more than 27% on Tuesday. Kidpik, last month, posted a Q3 loss of $0.22 per share.
Benzinga · 01/12 11:44
French Regulatory Authority Gives Green Signal To Phio Pharma's Melanoma Trial
The French National Agency for the Safety of Medicines and Health Products has signed off Phio Pharmaceuticals Corp's (NASDAQ: PHIO) clinical trial with
Benzinga · 01/11 17:08
Phio Pharma gets French regulatory nod to start clinical trial for lead asset
Phio Pharmaceuticals (NASDAQ:PHIO) is trading ~11.6% higher in the pre-market after announcing it obtained regulatory clearance from Frech authorities to start a clinical trial for its lead candidate PH-762 for melanoma. With
Seekingalpha · 01/11 13:05
BRIEF-Phio Pharmaceuticals Announces Regulatory Clearance Of Clinical Trial For PH-762 To Treat Melanoma
reuters.com · 01/11 12:47
Phio Pharmaceuticals Announces French Regulatory Clearance of Clinical Trial for PH-762 to Treat Melanoma
 Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform,
Benzinga · 01/11 12:31
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解PHIO最新的财务预测,通过PHIO每股收益,每股净资产,每股现金流等数据分析Phio Pharmaceuticals Corp近期的经营情况,然后做出明智的投资选择。
分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

0.00%强力推荐
100.00%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测PHIO价格均价为6.00,最高价位6.00,最低价为6.00。
最高6.00
均价6.00
最低6.00
现价0.8603
EPS
实际EPS
预期EPS
-0.34-0.25-0.17-0.08
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 22
机构持股: 150.25万
持股比例: 11.10%
总股本: 1,353.47万
类型机构数股数
增持
7
25.96万
建仓
3
3.16万
减持
5
3.19万
平仓
4
6.07万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-1.82%
制药与医学研究
-1.11%
高管信息
Non-Executive Chairman/Independent Director
Robert Bitterman
President/Chief Executive Officer
Gerrit Dispersyn
Independent Director
Geert Cauwenbergh
Independent Director
H. Paul Dorman
Independent Director
Robert Ferrara
Independent Director
Jonathan Freeman
Independent Director
Curtis Lockshin
暂无数据
PHIO 简况
Phio Pharmaceuticals Corp(原名:RXi Pharmaceuticals Corp)是一家生物技术公司。该公司基于其自我传递核糖核酸干扰(RNAi)(sd-rxRNA)治疗平台来开发免疫肿瘤治疗方法。其专注于通过检查点靶向或其他基因靶向,或者被用于瘤内注射免疫疗法来开发用于过继性细胞转移的sd-rxRNA治疗合成物。该公司的产品包括RXI-762和RXI-804。其sd-rxRNA化合物用来下调可能在一个疾病症状中过度表达的特定基因的表达。该公司正在开发RXI-762用于治疗用于治疗黑色素瘤、卵巢癌和其他缺陷。RXI-804是一个sd-rxRNA化合物,用来抑制免疫检查点蛋白质TIGIT的表达。

微牛提供Phio Pharmaceuticals Corp(NASDAQ-PHIO)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的PHIO股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易PHIO股票基本功能。